Switching Relapsing Multiple Sclerosis Patients Treated With Natalizumab at Risk for Progressive Multifocal Leukoencephalopathy to Teriflunomide: Is This Safe and Effective? (Sub-study: SWITCH-JCV)
Latest Information Update: 01 Feb 2023
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 10 Jan 2022 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
- 10 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 15 May 2020 Planned End Date changed from 1 Dec 2020 to 1 Dec 2021.